- Home
- C vs REGN Comparison
C vs REGN Comparison
Compare C & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- C
- REGN
- Stock Information
- Founded
- C 1812
- REGN 1988
- Country
- C United States
- REGN United States
- Employees
- C N/A
- REGN N/A
- Industry
- C Major Banks
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- C Finance
- REGN Health Care
- Exchange
- C Nasdaq
- REGN Nasdaq
- Market Cap
- C 116.8B
- REGN 110.0B
- IPO Year
- C N/A
- REGN 1991
- Fundamental
- Price
- C $69.82
- REGN $738.00
- Analyst Decision
- C Buy
- REGN Buy
- Analyst Count
- C 15
- REGN 24
- Target Price
- C $73.80
- REGN $1,110.63
- AVG Volume (30 Days)
- C 14.8M
- REGN 887.5K
- Earning Date
- C 01-15-2025
- REGN 10-31-2024
- Dividend Yield
- C 3.21%
- REGN N/A
- EPS Growth
- C N/A
- REGN 15.31
- EPS
- C 3.48
- REGN 40.43
- Revenue
- C $69,308,000,000.00
- REGN $13,847,100,000.00
- Revenue This Year
- C N/A
- REGN $10.13
- Revenue Next Year
- C $2.27
- REGN $4.00
- P/E Ratio
- C $20.05
- REGN $18.25
- Revenue Growth
- C N/A
- REGN 5.72
- 52 Week Low
- C $44.56
- REGN $735.95
- 52 Week High
- C $70.20
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- C 63.86
- REGN 13.13
- Support Level
- C $67.70
- REGN $735.95
- Resistance Level
- C $69.49
- REGN $757.56
- Average True Range (ATR)
- C 1.25
- REGN 18.56
- MACD
- C 0.05
- REGN -1.24
- Stochastic Oscillator
- C 94.96
- REGN 1.89
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).